Caring for the Renal Failure Patient: Optimizing Iron Therapy

ANNA Breakfast Symposium
May 2002
Access to this symposium is free, but you must first be a registered FREE ZONE user of HDCN. If not already an HDCN FREE ZONE user, please register at this link and select a username and password.
Current Practices in Iron Management
Vaughn W. Folkert, MD.
A Protocol for PD and CKD Patients
Asuncion M. Javier, RN, BSN.
IV Iron Therapy and Maintenance Outcomes
Neeta B. O'Mara, PharmD, BCPS.
Panel Discussion
V. Folkert, A. Javier, and N. O'Mara



After participating in this program, the learner should be able to:
  1. Discuss recent data in treating PD and CKD patients with newer IV iron therapies.
  2. Discuss current practices in caring for ESRD patients with iron deficiency anemia.
  3. Identify safe and effective treatment options for improving ESRD patient outcomes.
Vaughn W. Folkert, MD.
Director, Baumritter Kidney Center
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, New York

Asuncion M. Javier, RN, BSN
Clinical Nurse Consultant
University of Illinois at Chicago
Chicago, Illinois

Neeta B. O'Mara, PharmD, BCPS
Clinical Pharmacist
Dialysis Clinic, Inc.
North Brunswick, New Jersey

The series of talks is approved for 1.7 Contact Hours by the American Nephrology Nurses' Association (ANNA) .
Date of Original Release: August 17, 2002
CE Credit Eligible Through: August 17, 2003
Contact Hours/Completion Time: 1.7
Target Audiences: Nephrology nurses and technicians.
Method of participation: Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the linked abstracts in the post-test, answer feedback material.

STATEMENT OF NEED :
Chronic kidney disease affects 30-40 million Americans, of whom several hundred thousand require renal replacement therapy. These selected lectures will allow nephrology nurses, pharmacists, and technicians to obtain up-to-date information about issues related to care of renal patients.

ACCREDITATION STATEMENT:
This continuing education activity is based on an approved Satellite Symposium which took place at the American Nephrology Nurses' Association (ANNA) 2002 Annual Meeting, and is approved by ANNA, East Holley Avenue, Box 56, Pitman, New Jersey 08071-0056, an accredited approver by the American Nurse Credentialing Center Commission on Accreditation (ANCC-COA). ANNA is an approved provider of CE to nursing by the California Board of Registered Nursing, BRN Provider No. 00910, the Alabama Board of Nursing, BRN Provider No. PO324, and the Kansas State Board of Nursing, Provider No. LT0148-0738. This course offering is applicable for RN and LPN licensure in Kansas. Licensees in the states of CA, AL, and KS must retain this certificate for four years after the CE activity is completed. Other mandatory CE states may have different record keeping requirements. Please be aware of your state's procedure.

The activity provider is HDCN, 15W560 89th St., Hinsdale, IL 60527.

FACULTY DISCLOSURE STATEMENTS :
The American Nephrology Nurses' Association, as well as HDCN have conflict of interest policies that require course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted here to fully inform participants.

V. Folkert is a speakers' bureau participant for Ortho Biotech and Watson Pharma Inc.
A. M. Javier has received grants/research support from Ortho Biotech and is a speakers' bureau participant for Watson Pharma Inc.
N. O'Mara is a stock/shareholder in BMS, Pfizer, Merck, and Wyeth and is a speakers' bureau participant for Genentech and American Bone Care.
DISCLOSURE OF UNLABELED USE:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The American Nephrology Nurses' Association, and HDCN do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This educational activity is supported by an educational grant from Watson Pharmaceuticals Inc.
This activity has been planned and produced in accordance with CE Guidelines and Policies.
This educational activity is based on an official ANNA breakfast symposium, but the program was not planned by the ANNA Program Committee.